Gilead Acquires Arcellx for $7.8 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ACLX?
Source: stocktwits
Arcellx Inc's stock surged 78.13% in pre-market trading, reaching a 52-week high, following Gilead's announcement of its acquisition agreement.
Gilead Sciences has entered into a definitive agreement to acquire Arcellx for $115 per share in cash, totaling $7.8 billion. This acquisition reflects Gilead's confidence in Arcellx's innovative therapies, particularly the potential FDA approval of Anito-cel for multiple myeloma, which is expected to enhance Gilead's market position significantly. The deal is anticipated to close in Q2 2026, with Gilead projecting an increase in earnings per share starting in 2028, driven by the expected success of Anito-cel.
The acquisition is seen as a strategic move for Gilead, solidifying its leadership in oncology and expanding its portfolio in blood cancer treatments. The strong market reaction to the acquisition indicates heightened investor interest in Arcellx, which may lead to further stock price appreciation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACLX
Wall Street analysts forecast ACLX stock price to fall
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 114.390
Low
100.00
Averages
113.14
High
130.00
Current: 114.390
Low
100.00
Averages
113.14
High
130.00
About ACLX
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Arcellx, Inc. (NASDAQ:ACLX) regarding its sale to Gilead Sciences, Inc. for $115 per share in cash plus a $5 contingent value right, which may impact shareholder rights and options.
- Transaction Terms Limitation: The sale of DigitalBridge Group, Inc. (NYSE:DBRG) to SoftBank Group Corp. for $16 per share in cash may contain terms that limit superior competing offers, affecting potential shareholder returns.
- Merger Impact: The merger between Mission Produce, Inc. (NASDAQ:AVO) and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, potentially altering the competitive landscape in the market.
- Legal Rights Protection: Halper Sadeh LLC encourages shareholders to consult on their rights at no cost, potentially seeking increased consideration and other remedies to safeguard investor interests.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Arcellx, Inc. and Gilead Sciences, Inc., where Arcellx shareholders are expected to receive $115 per share in cash plus a contingent value right of $5 per share upon achieving certain milestones, potentially providing significant returns for shareholders.
- DigitalBridge Group Transaction: The firm is also focusing on the transaction between DigitalBridge Group, Inc. and SoftBank Group, where DigitalBridge shareholders are expected to receive $16 per share in cash, offering direct cash benefits to shareholders.
- Merger Case Analysis: Monteverde Law Firm is examining the merger between Mission Produce, Inc. and Calavo Growers, Inc., where Calavo shareholders will receive 0.9790 shares of Mission Produce common stock and $14.85 in cash per share, which could reshape market dynamics.
- Commitment to Legal Services: The firm emphasizes its successful track record in securities class actions, dedicated to advocating for shareholder rights and ensuring that all companies and their executives adhere to the law, showcasing its professionalism and accountability in the legal field.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Brink’s Company and NCR Atleos Corporation, where Brink’s shareholders will own approximately 78% of the combined entity, potentially impacting shareholder rights and future returns.
- Shareholder Rights Protection: The sale of Thermon Group Holdings, Inc. to CECO Environmental Corp. offers multiple options, including $10.00 in cash plus 0.6840 shares of CECO stock per Thermon share, or $63.89 per share, or 0.8110 shares of CECO stock, necessitating shareholders to understand their rights and choices.
- Cash Acquisition Opportunity: Arcellx, Inc. is being sold to Gilead Sciences, Inc. for $115.00 per share in cash, along with a contingent value right of $5.00 per share, prompting shareholders to pay attention to the transaction terms and their impact on investment returns.
- Legal Support Services: Halper Sadeh LLC offers risk-free legal consultation services, allowing shareholders to learn about their rights and potential compensation in merger transactions without incurring legal fees, aiming to protect investors' legitimate interests.
See More
Monteverde Law Firm Investigates Multiple Company Transactions
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Arcellx, Inc. and Gilead Sciences, Inc., where Arcellx shareholders are expected to receive $115 per share in cash plus a contingent value right of $5 per share, aimed at protecting shareholder interests and ensuring transaction fairness.
- Veris Residential Transaction: Shareholders of Veris Residential, Inc. are expected to receive $19 per share in cash, with the deal led by Affinius Capital and Vista Hill Partners, reflecting investor confidence in the real estate market and its potential returns.
- Enhabit Acquisition: The transaction between Enhabit Inc. and Kinderhook Industries, LLC is expected to provide shareholders with $13.80 per share in cash, highlighting ongoing market interest and investment enthusiasm in the healthcare services sector.
- CECO Merger: The merger of CECO Environmental Corp. with Thermon Group Holdings, Inc. is projected to result in CECO shareholders owning approximately 62.5% of the combined company, indicating a strategic consolidation in the environmental services sector and future growth potential.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as Arcellx, Inc., Veris Residential, Inc., and Enhabit, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Arcellx Transaction: Arcellx, Inc. is being sold to Gilead Sciences, Inc. for $115.00 per share in cash plus a contingent value right of $5.00 per share, which may limit superior competing offers and affect potential shareholder returns.
- Veris Transaction: Veris Residential, Inc. is being sold for $19.00 per share to an investor consortium led by Affinius Capital and Vista Hill Partners, and Halper Sadeh LLC may seek to increase the consideration to protect shareholder interests.
- Enhabit Transaction: Enhabit, Inc. is being sold to Kinderhook Industries, LLC for $13.80 per share in cash, and Halper Sadeh LLC encourages shareholders to reach out to understand their rights and options to ensure their legal interests are protected.
See More
Healthcare Stocks Show Overbought Warning Signals
- Overbought Signals: As of March 4, 2026, Anika Therapeutics Inc (NASDAQ:ANIK) and Arcellx Inc (NASDAQ:ACLX) are identified as major overbought stocks in the healthcare sector, with RSI indicators exceeding 70, signaling caution for investors.
- Momentum Indicator Analysis: The RSI serves as a momentum indicator by comparing a stock's strength on up days versus down days, aiding traders in assessing short-term stock performance; an overbought condition may lead to price corrections, impacting investment decisions.
- Market Reaction Expectations: The emergence of overbought signals may prompt investors to reassess the short-term investment value of these two stocks, potentially leading to capital outflows that could affect stock price movements.
- Industry Trend Observation: The overbought phenomenon in the healthcare sector may reflect excessive optimism in the market towards certain companies, necessitating investors to monitor overall market sentiment and fundamental changes in related stocks to formulate more rational investment strategies.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Arcellx, Inc. (NASDAQ:ACLX) regarding its sale to Gilead Sciences, Inc. for $115 per share in cash plus a $5 contingent value right, which may impact shareholder rights and options.
- Transaction Terms Limitation: The sale of DigitalBridge Group, Inc. (NYSE:DBRG) to SoftBank Group Corp. for $16 per share in cash may contain terms that limit superior competing offers, affecting potential shareholder returns.
- Merger Impact: The merger between Mission Produce, Inc. (NASDAQ:AVO) and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, potentially altering the competitive landscape in the market.
- Legal Rights Protection: Halper Sadeh LLC encourages shareholders to consult on their rights at no cost, potentially seeking increased consideration and other remedies to safeguard investor interests.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Arcellx, Inc. and Gilead Sciences, Inc., where Arcellx shareholders are expected to receive $115 per share in cash plus a contingent value right of $5 per share upon achieving certain milestones, potentially providing significant returns for shareholders.
- DigitalBridge Group Transaction: The firm is also focusing on the transaction between DigitalBridge Group, Inc. and SoftBank Group, where DigitalBridge shareholders are expected to receive $16 per share in cash, offering direct cash benefits to shareholders.
- Merger Case Analysis: Monteverde Law Firm is examining the merger between Mission Produce, Inc. and Calavo Growers, Inc., where Calavo shareholders will receive 0.9790 shares of Mission Produce common stock and $14.85 in cash per share, which could reshape market dynamics.
- Commitment to Legal Services: The firm emphasizes its successful track record in securities class actions, dedicated to advocating for shareholder rights and ensuring that all companies and their executives adhere to the law, showcasing its professionalism and accountability in the legal field.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Brink’s Company and NCR Atleos Corporation, where Brink’s shareholders will own approximately 78% of the combined entity, potentially impacting shareholder rights and future returns.
- Shareholder Rights Protection: The sale of Thermon Group Holdings, Inc. to CECO Environmental Corp. offers multiple options, including $10.00 in cash plus 0.6840 shares of CECO stock per Thermon share, or $63.89 per share, or 0.8110 shares of CECO stock, necessitating shareholders to understand their rights and choices.
- Cash Acquisition Opportunity: Arcellx, Inc. is being sold to Gilead Sciences, Inc. for $115.00 per share in cash, along with a contingent value right of $5.00 per share, prompting shareholders to pay attention to the transaction terms and their impact on investment returns.
- Legal Support Services: Halper Sadeh LLC offers risk-free legal consultation services, allowing shareholders to learn about their rights and potential compensation in merger transactions without incurring legal fees, aiming to protect investors' legitimate interests.
See More
Monteverde Law Firm Investigates Multiple Company Transactions
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Arcellx, Inc. and Gilead Sciences, Inc., where Arcellx shareholders are expected to receive $115 per share in cash plus a contingent value right of $5 per share, aimed at protecting shareholder interests and ensuring transaction fairness.
- Veris Residential Transaction: Shareholders of Veris Residential, Inc. are expected to receive $19 per share in cash, with the deal led by Affinius Capital and Vista Hill Partners, reflecting investor confidence in the real estate market and its potential returns.
- Enhabit Acquisition: The transaction between Enhabit Inc. and Kinderhook Industries, LLC is expected to provide shareholders with $13.80 per share in cash, highlighting ongoing market interest and investment enthusiasm in the healthcare services sector.
- CECO Merger: The merger of CECO Environmental Corp. with Thermon Group Holdings, Inc. is projected to result in CECO shareholders owning approximately 62.5% of the combined company, indicating a strategic consolidation in the environmental services sector and future growth potential.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as Arcellx, Inc., Veris Residential, Inc., and Enhabit, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Arcellx Transaction: Arcellx, Inc. is being sold to Gilead Sciences, Inc. for $115.00 per share in cash plus a contingent value right of $5.00 per share, which may limit superior competing offers and affect potential shareholder returns.
- Veris Transaction: Veris Residential, Inc. is being sold for $19.00 per share to an investor consortium led by Affinius Capital and Vista Hill Partners, and Halper Sadeh LLC may seek to increase the consideration to protect shareholder interests.
- Enhabit Transaction: Enhabit, Inc. is being sold to Kinderhook Industries, LLC for $13.80 per share in cash, and Halper Sadeh LLC encourages shareholders to reach out to understand their rights and options to ensure their legal interests are protected.
See More
Healthcare Stocks Show Overbought Warning Signals
- Overbought Signals: As of March 4, 2026, Anika Therapeutics Inc (NASDAQ:ANIK) and Arcellx Inc (NASDAQ:ACLX) are identified as major overbought stocks in the healthcare sector, with RSI indicators exceeding 70, signaling caution for investors.
- Momentum Indicator Analysis: The RSI serves as a momentum indicator by comparing a stock's strength on up days versus down days, aiding traders in assessing short-term stock performance; an overbought condition may lead to price corrections, impacting investment decisions.
- Market Reaction Expectations: The emergence of overbought signals may prompt investors to reassess the short-term investment value of these two stocks, potentially leading to capital outflows that could affect stock price movements.
- Industry Trend Observation: The overbought phenomenon in the healthcare sector may reflect excessive optimism in the market towards certain companies, necessitating investors to monitor overall market sentiment and fundamental changes in related stocks to formulate more rational investment strategies.
See More
